the aid library

LIST OPTIONS

Filter

1156

Sort by:

Direction:

Download (2166)

View PDF (2780)

Polio Eradication and Endgame Strategic Plan 2013-2018

Global Polio Eradication Intiative (2013)

The WHO Global Polio Eradication Initiative (GPEI)’s new Polio Eradication and Endgame Strategic Plan targets the end of all kinds of polioviruses by 2018, including the wild and rare vaccine-related strains which cause paralysis among thousands of children worldwide. The plan is focused on develo... more

Download (68)

View PDF (852)

WHO COVID-19 Detailled Surveillance Data Dashboard
recommended

World Health Organization WHO (2021) C_WHO

Over 18 months into the pandemic, WHO continues to conductglobal surveillance of COVID-19as part of activities on preparedness, readiness and response activities. The need for global surveillance of COVID-19 is greater than ever, asthe implementation of vaccination campaigns and the appearance of va... more

Download (88)

View PDF (117)

Orientations sur la sécurité biologique en laboratoire en rapport avec la maladie à coronavirus 2019 (‎‎COVID-19)
recommended

Organisation Mondiale de la Santé OMS (2021) C_WHO

‎‎Orientations provisoires, 28 janvier 2021 Dans cette version mise à jour des orientations sur la sécurité biologique en laboratoire en rapport avec le SARS-CoV-2, le virus responsable de la maladie à coronavirus 2019 (COVID-19), les points suivants ont été ajoutés : aspects de... more

Download (97)

View PDF (154)

Policy considerations for implementing a risk-based approach to international travel in the context of COVID-19, 2 July 2021

World Health Organization WHO (2021) C_WHO

Countries across the world are facing diverse epidemiological situations with varying response capacities and access to life saving tools. The World Health Organization (WHO) recommends that national authorities continue to apply a risk-based approach when implementing measures related to COVID-19... more

Download (106)

View PDF (181)

Considérations politiques relatives à la mise en oeuvre d’une approche fondée sur les risques pour les voyages internationaux dans le cadre de la COVID-19, 2 juillet 2021

Organisation mondiale de la Santé OMS (2021) C_WHO

Les pays du monde entier sont confrontés à des situations épidémiologiques diverses, et disposent de capacités de réaction différentes et d’un accès inégal aux outils permettant de sauver des vies. L’Organisation mondiale de la Santé (OMS) recommande aux autorités nationales de contin... more

Download (50)

View PDF (699)

Mettre fin à la propagation du virus

Organisation Mondiale de la Santé OMS (2021) C_WHO

Lorsqu’un virus circule largement dans une population et entraîne de nombreuses infections, la probabilité de mutation augmente. Plus un virus a de possibilités de se propager, plus il se réplique – et plus il est susceptible de muter. L’arrêt de la propagation du virus à la source res... more

Download (98)

View PDF (121)

Strategy to Achieve Global Covid-19 Vaccination by mid-2022

World Health Organisation (WHO) (2021) C_WHO

Every country has been affected by COVID-19, with nearly a quarter of a billion cases and almost 5 million deaths reported globally as of end of September 2021. Despite the stunning speed with which highly effective and safe vaccines have been developed, new waves of disease are still pushin... more

Download (94)

View PDF (130)

Guidance on administration of COVID-19 vaccine boosters in Africa
recommended

African Union; Africa CDC Centres for Disease Control and Prevention (2022) CC

17 Febr. 2022. As part of the “Strategy to Achieve Global COVID-19 Vaccination by mid-2022”, global targets of 40% population coverage by end of 2021 and 70% coverage by June 2022 have been set by the World Health Organization (WHO), to successfully prevent severe illness and deaths, minimize so... more

Download (211)

View PDF (208)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 25 April 2022: updated chapter: mask use, part 1: health care settings
recommended

World Health Organization WHO (2022) C_WHO

22 April 2022, This document provides updated interim recommendations on the use of masks by health workers providing care to patients with suspected or confirmed COVID-19. This update is prompted by new evidence around mask use and COVID-19 transmission, as well as the emergence of variants of conc... more

Download (67)

View PDF (574)

The successful COVID-19 vaccine rollout in Chile: Factors and challenges

Castillo C., Villalobos Dintrans P. et al (2021) C2

The aim of this article is to identify the elements behind the country’s successful COVID-19 rollout as well as lessons and chal lenges derived from this process. The analysis is relevant to many countries today—as they keep searching for strategies to cope with the second year of the COVID-19 p... more

Download (136)

View PDF (166)

Covid-19 Test to Treat Guidelines
recommended

African Union; Africa CDC Centres for Disease Control and Prevention (2022) C1

n response to the outbreak, the Africa Centres for Disease Control and Prevention (Africa CDC) has been supporting African Union Member States in responding to the COVID-19 pandemic through a variety of interventions such as non-pharmaceutical interventions, quarantine, testing, isolation, contact t... more

Download (106)

View PDF (165)

Dengue epidemiology

Jing, Q.; Wang, M. Global Health Journal (2019) CC

Dengue is the fastest spreading, mosquito-borne viral infectious disease worldwide, with remarkable morbidity and mortality. In the past decades, profound contributions have been made towards understanding its epidemiology, including disease burden and distributions, risk factors, and control and pr... more

Download (59)

View PDF (637)

Rabies around the World

Center for Disease Control and Prevention CDC (2020) CC

Each year, rabies causes approximately 59,000 deaths worldwide. Despite evidence that control of dog rabies through animal vaccination programs and elimination of stray dogs can reduce the incidence of human rabies, dog rabies remains common in many countries and exposure to rabid dogs is still the ... more

Download (90)

View PDF (128)

Compendium of Animal Rabies Prevention and Control, 2016

Brown C.M., Slavinski S., Ettestad P. et al National Association of State Public Health Veterinarians Compendium of Animal Rabies Prevention and Control Committee (2016) C2

Rabies is a fatal viral zoonosis and serious public health problem.1 All mammals are believed to be susceptible to the disease, and for the purposes of this document, use of the term animal refers to mammals. The disease is an acute, progressive encephalitis caused by viruses in the genus Lyssavirus... more

Download (128)

View PDF (186)

World Urbanization Prospects. The 2018 Revision

United nations. Department of Economic and Social Affairs (2019) CC

This report presents the results of the official United Nations estimates and projections of urban and rural populations for 233 countries and areas of the world and for close to 1,900 urban settlements with 300,000 inhabitants or more in 2018, as published in World Urbanization Prospects: The 2018 ... more

Download (47)

View PDF (72)

ACT-Accelerator Prioritized Strategy & Budget for 2021

World Health Organization (WHO), The Global Fund, Gavi et al. World Health Organization (WHO) (2021) CC

In 2021 ACT-Accelerator will intensify its drive for equity and scale in the delivery of essential COVID-19 tools, while managing emerging viral risks. To address these major shifts and maintain momentum, ACT-Accelerator has defined four strategic priorities for 2021: Rapidly scale up the delivery o... more

Download (100)

View PDF (384)

Donor Funding for Newborn Survival: An Analysis of Donor-Reported Data, 2002–2010

Pitt1, C.; J. E. Lawn; M. Ranganathan et al. PLoS Med (2012) CC

Background:Neonatal mortality accounts for 43% of global under-five deaths and is decreasing more slowly than maternal or child mortality. Donor funding has increased for maternal, newborn, and child health (MNCH), but no analysis to date has disaggregated aid for newborns. We evaluated if and how a... more

Download (245)

View PDF (330)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (27)

View PDF (18)

Annual Report: Global Polio Eradication Initiative

World Health Organisation (WHO) (2024) CC

The key to a lasting world free of all forms of poliovirus lies in rapidly interrupting all remaining endemic transmission of WPV in the endemic areas of Pakistan and Afghanistan. This is the only way to ensure that such strains do not re-emerge globally through international spread. It lays the cor... more

Download (7)

View PDF (6)

Mpox Testing Strategy - November 2024

Africa Center for Disease Control and Prevention (2024) CC

Mpox is an emerging zoonotic disease caused by the mpox virus, a member of the Orthopoxvirus genus closely related to the variola virus that causes smallpox. Mpox was first discovered in 1958 when outbreaks of a pox-like disease occurred in monkeys kept for research. The first human case was recorde...d in 1970 in the Democratic Republic of the Congo (DRC) during a period of intensified effort to eliminate smallpox and since then the infection has been reported in a number of African countries. Mpox can spread in humans through close contact, usually skin-to-skin contact, including sexual contact, with an infected person or animal, as well as with materials contaminated with the virus such as clothing, beddings and towels, and respiratory droplets in prolonged face to face contact. People remain infectious from the onset of symptoms until all the lesions have scabbed and healed. The virus may spread from infected animals through handling infected meat or through bites or scratches. Diagnosis is confirmed by polymerase chain reaction (PCR) testing of material from a lesion for the virus’s DNA. Two separate clades of the mpox virus are currently circulating in Africa: Clade I, which includes subclades Ia and Ib, and Clade II, comprising subclades IIa and IIb. Clade Ia and Clade Ib have been associated with ongoing human-to-human transmission and are presently responsible for outbreaks in the Democratic Republic of the Congo (DRC), while Clade Ib is also contributing to outbreaks in Burundi and other countries. In 2022‒2023 mpox caused a global outbreak in over 110 countries, most of which had no previous history of the disease, primarily driven by human-to-human transmission of clade II through sexual contact. In just over a year, over 90,000 cases and 150 deaths were reported to the WHO. For the second time since 2022, mpox has been declared a global health emergency as the virus spreads rapidly across the African continent. On 13 Aug 2024, Africa CDC declared the ongoing mpox outbreak a Public Health Emergency of Continental Security (PHECS), marking the first such declaration by the agency since its inception in 2017.7 This declaration empowered the Africa CDC to lead and coordinate responses to the mpox outbreak across affected African countries. On August 14, 2024, the WHO declared the resurgence of mpox a Public Health Emergency of International Concern (PHEIC) emphasizing the need for coordinated international response. As of August 2024, Mpox has expanded beyond its traditional endemic regions, with new cases reported in countries including Sweden, Thailand, the Philippines, and Pakistan. Sweden has confirmed its first case of Clade 1 variant, which has been rapidly spreading in Africa, particularly in DRC. The emergence of this new variant raises concerns about its potential for higher lethality and transmission rates outside Africa. more

WHO COVID-19 Detailled Surveillance Data Dashboard recommended

Orientations sur la sécurité biologique en laboratoire en rapport avec la maladie à coronavirus 2019 (‎‎COVID-19) recommended

Guidance on administration of COVID-19 vaccine boosters in Africa recommended

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 25 April 2022: updated chapter: mask use, part 1: health care settings recommended

Covid-19 Test to Treat Guidelines recommended

WHO COVID-19 Detailled Surveillance Data Dashboard
recommended

Orientations sur la sécurité biologique en laboratoire en rapport avec la maladie à coronavirus 2019 (‎‎COVID-19)
recommended

Guidance on administration of COVID-19 vaccine boosters in Africa
recommended

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 25 April 2022: updated chapter: mask use, part 1: health care settings
recommended

Covid-19 Test to Treat Guidelines
recommended